Genaera Releases Mid-Term Data on Diabetes Drug

Genaera received favorable interim findings from its second Phase I trial with trodusquemine, the company’s lead drug candidate for the treatment of Type 2 diabetes and obesity.

The results suggest that the drug was well tolerated by overweight and obese volunteers with Type 2 diabetes. There was a low level of adverse events and no evidence of serious adverse events.

Trodusquemine (MSI-1436) is an appetite suppressant and a highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), which controls the function of the leptin and insulin pathways. By inhibiting PTP1B, the drug is expected to decrease appetite and normalize blood sugar, Genaera said.